Neurolixis is a biotechnology company that specializes in the development of innovative molecules for the treatment of central nervous system diseases. With a focus on addressing unmet needs in psychiatric and neurological disorders, Neurolixis has a promising pipeline of compounds in both clinical and preclinical phases. Their lead compounds include NLX-112 for movement disorders, NLX-101 for autism spectrum disorders, and NLX-204 for depression and pain.

Privately held and funded by research grants from esteemed foundations like Parkinson's UK, the Michael J. Fox Foundation for Parkinson's Research, and the Rett Syndrome Research Trust, Neurolixis is fully dedicated to advancing groundbreaking research in the field. Their therapeutic focus extends to movement disorders such as dyskinesia in Parkinson's disease, autism spectrum disorders including Rett syndrome and Fragile X syndrome, as well as depression and pain.

Neurolixis is committed to making a significant impact on the lives of patients suffering from these conditions. Neurolixis is at the forefront of innovation in biotechnology, striving to develop novel solutions that will revolutionize the treatment of central nervous system diseases